Rocket Doctor Ai Inc. (TREIF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rocket Doctor Ai Inc. (TREIF) trades at $0.49. Rocket Doctor AI is focused on improving the healthcare sector through AI-driven solutions. Market cap: $36.62M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for TREIF: TREIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TREIF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TREIF: 1/1 perspectives are bearish.
Rocket Doctor Ai Inc. (TREIF) Healthcare & Pipeline Overview
Rocket Doctor AI leverages artificial intelligence to enhance healthcare efficiency, offering the Global Library of Medicine (GLM) to streamline clinical workflows. With a focus on reducing administrative burdens for healthcare professionals, the company operates in the evolving healthcare information services sector, facing competition and regulatory hurdles.
What Is the Investment Thesis for TREIF?
Rocket Doctor AI presents a high-risk, high-reward investment opportunity within the healthcare information services sector. The company's focus on AI-driven solutions, particularly the Global Library of Medicine (GLM), could address critical inefficiencies in healthcare administration. However, the company's negative P/E ratio of -4.51 and a substantial negative profit margin of -1670.1% indicate significant financial challenges. The company's small market capitalization of $0.04 billion and limited number of employees (3) suggest it is in an early stage of development. Potential investors should carefully consider the risks associated with investing in a small, unprofitable company operating in a competitive and highly regulated industry. The beta of -0.43 suggests the stock is less volatile than the market.
Based on FMP financials and quantitative analysis
TREIF Key Highlights
- Market capitalization of $0.04 billion indicates a micro-cap company with potential for high growth but also significant risk.
- Negative P/E ratio of -4.51 reflects current unprofitability, requiring careful evaluation of future earnings potential.
- Gross margin of 89.4% suggests a strong pricing power and efficient cost management in delivering its AI-driven healthcare solutions.
- Profit margin of -1670.1% highlights significant operational inefficiencies or high initial investment costs, demanding scrutiny of the company's financial strategy.
- Beta of -0.43 indicates lower volatility compared to the market, which may appeal to risk-averse investors but could also limit potential gains.
Who Are TREIF's Competitors?
Who Are TREIF's Competitors?
TREIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DMTTF Small Pharma Inc. | $0.11 | +0.00% | $37.51M | 44 |
| HNGE Hinge Health, Inc. | $54.50 | +1.15% | 5B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.00 | +0.00% | $20.00M | 67 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| FOXO FOXO Technologies Inc. | $0.00 | +0.00% | 3K | 63 |
| GEHC GE HealthCare Technologies Inc. | $64.67 | -3.05% | $29.42B | 52 |
| HCAT Health Catalyst, Inc. | $1.29 | +14.00% | $95.32M | 52 |
| AMWL American Well Corporation (AMWL) | $7.80 | -1.39% | 131M | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TREIF's Key Strengths?
- Innovative AI-powered healthcare solutions.
- Comprehensive Global Library of Medicine (GLM).
- Potential to reduce administrative burdens for healthcare professionals.
What Are TREIF's Weaknesses?
- Small market capitalization and limited resources.
- Negative P/E ratio and profit margin.
- Limited number of employees.
What Could Drive TREIF Stock Higher?
- Potential partnerships with healthcare providers or telehealth platforms could drive adoption of the GLM.
- Positive results from clinical trials or studies validating the effectiveness of the GLM.
- Increasing adoption of AI-powered solutions in the healthcare sector.
- Expansion of the Global Library of Medicine (GLM) with more medical reviews and clinical guidelines.
- Regulatory approvals or certifications for the GLM in new markets.
What Are the Key Risks for TREIF?
- Intense competition in the healthcare information services sector.
- Complex regulatory landscape and potential for changes in healthcare regulations.
- Technological obsolescence and the need to continuously innovate.
- Limited financial resources and the need to raise additional capital.
- Dependence on key personnel and the risk of losing talent.
What Are the Growth Opportunities for TREIF?
- Expansion of the Global Library of Medicine (GLM): Rocket Doctor AI can expand the GLM by incorporating more medical reviews, clinical guidelines, and diagnostic tools. This would enhance the GLM's value proposition and attract a larger user base of healthcare professionals. The market for clinical decision support systems is projected to reach $3.2 billion by 2027, providing a significant growth opportunity for Rocket Doctor AI.
- Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and other healthcare organizations can provide Rocket Doctor AI with access to a wider network of users and valuable data for improving the GLM. Strategic partnerships can also enhance the company's credibility and market presence. The healthcare provider market is vast and diverse, offering numerous partnership opportunities for Rocket Doctor AI.
- Integration with Telehealth Platforms: Integrating the GLM with telehealth platforms can provide healthcare professionals with seamless access to clinical information and support during virtual consultations. This would enhance the efficiency and effectiveness of telehealth services and create a new revenue stream for Rocket Doctor AI. The telehealth market is experiencing rapid growth, driven by increasing demand for remote healthcare services.
- Geographic Expansion: Rocket Doctor AI can expand its operations beyond Canada and target new markets in the United States, Europe, and Asia. This would increase the company's potential customer base and diversify its revenue streams. The global healthcare market is vast and diverse, offering significant growth opportunities for Rocket Doctor AI.
- Development of New AI-Powered Solutions: Rocket Doctor AI can leverage its expertise in artificial intelligence to develop new solutions for other healthcare challenges, such as drug discovery, personalized medicine, and patient monitoring. This would expand the company's product portfolio and create new revenue streams. The market for AI in healthcare is projected to reach $45.2 billion by 2026, providing a significant growth opportunity for Rocket Doctor AI.
What Opportunities Does TREIF Have?
- Expansion of the GLM and development of new AI-powered solutions.
- Partnerships with healthcare providers and telehealth platforms.
- Geographic expansion into new markets.
What Threats Does TREIF Face?
- Intense competition in the healthcare information services sector.
- Complex regulatory landscape.
- Potential for technological obsolescence.
What Are TREIF's Competitive Advantages?
- Proprietary AI Technology: The Global Library of Medicine (GLM) and its underlying AI algorithms may provide a competitive advantage.
- Expert Medical Reviews: The incorporation of over 10,000 expert medical reviews enhances the credibility and reliability of the GLM.
- Data Network Effects: As more healthcare professionals use the GLM, the AI engine can learn and improve, creating a network effect.
What Does TREIF Do?
Rocket Doctor AI, founded with the mission of revolutionizing the healthcare sector, utilizes artificial intelligence and clinical best practices to address inefficiencies and challenges. The company's core product, the Global Library of Medicine (GLM), is a comprehensive, personalized healthcare AI engine developed with input from hundreds of healthcare professionals globally. The GLM provides tested clinical information, recommended tests, imaging guidance, and billing codes to doctors, nurses, and pharmacists, aiming to reduce their administrative workload. Rocket Doctor AI's GLM incorporates over 10,000 expert medical reviews, ensuring that healthcare professionals have access to up-to-date and reliable information. The company operates in the healthcare information services sector, which is characterized by rapid technological advancements and increasing demand for efficient healthcare solutions. Rocket Doctor AI is headquartered in Vancouver, Canada, and currently employs a small team of three individuals.
What Products and Services Does TREIF Offer?
- Develops AI-powered solutions for the healthcare sector.
- Creates and maintains the Global Library of Medicine (GLM), a comprehensive healthcare AI engine.
- Provides clinical information and support to healthcare professionals.
- Offers recommended tests, imaging guidance, and billing codes.
- Aims to reduce administrative burdens for doctors, nurses, and pharmacists.
- Utilizes expert medical reviews to ensure the accuracy and reliability of the GLM.
How Does TREIF Make Money?
- Software as a Service (SaaS): Likely offers subscriptions to access the Global Library of Medicine (GLM).
- Partnerships: May generate revenue through partnerships with healthcare providers and telehealth platforms.
- Data Analytics: Could potentially monetize anonymized data insights derived from GLM usage.
What Industry Does TREIF Operate In?
Rocket Doctor AI operates within the healthcare information services industry, a sector experiencing rapid growth driven by technological advancements and increasing demand for efficient healthcare solutions. The industry is characterized by intense competition, with established players and emerging startups vying for market share. Key trends include the adoption of AI and machine learning, the rise of telehealth, and the increasing focus on data analytics to improve patient outcomes and reduce costs. Rocket Doctor AI's success will depend on its ability to differentiate itself from competitors and navigate the complex regulatory landscape.
Who Are TREIF's Key Customers?
- Doctors
- Nurses
- Pharmacists
- Hospitals and Clinics
- Telehealth Providers
TREIF Financials
TREIF Latest News
No recent news available for TREIF.
TREIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TREIF.
Price Targets
Wall Street price target analysis for TREIF.
TREIF MoonshotScore
What does this score mean?
The MoonshotScore rates TREIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Essam Hamza
CEO
Essam Hamza is the CEO of Rocket Doctor AI, a company focused on leveraging AI to improve healthcare. Information regarding his prior experience and educational background is not available. As CEO, he is responsible for the overall strategic direction and management of the company. He currently manages a small team of three employees.
Track Record: Due to the limited information available, it is difficult to assess Essam Hamza's track record. The company is still in its early stages, and there is limited public information available regarding key achievements or strategic decisions under his leadership.
TREIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Rocket Doctor AI may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and prospects. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ, due to the lower regulatory oversight and increased potential for fraud or manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of comprehensive financial reporting makes it difficult to assess the company's financial health and prospects.
- Low Liquidity: Limited trading volume and wide bid-ask spreads increase the risk of price manipulation and make it challenging to buy or sell shares.
- Regulatory Uncertainty: OTC Other stocks are subject to less regulatory oversight than stocks listed on major exchanges, increasing the risk of fraud or manipulation.
- Going Concern Risk: Companies trading on the OTC Other market may be facing financial difficulties or have a higher risk of bankruptcy.
- Information Asymmetry: The lack of readily available information can create an uneven playing field for investors.
- Verify the company's registration and legal standing.
- Obtain and review any available financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the company's capital structure and potential dilution.
- Consult with a qualified financial advisor.
- Be aware of the risks associated with investing in OTC Other stocks.
- Company has a functional website with contact information.
- Company has a clear business plan and value proposition.
- Company has a management team with relevant experience.
TREIF Healthcare Stock FAQ
What does Rocket Doctor Ai Inc. do?
Rocket Doctor AI aims to revolutionize healthcare by leveraging artificial intelligence. Its core product, the Global Library of Medicine (GLM), is designed to assist healthcare professionals by providing clinical information, recommended tests, imaging guidance, and billing codes. By streamlining administrative tasks and offering AI-driven support, Rocket Doctor AI seeks to improve efficiency and patient outcomes within the healthcare sector. The company is still in its early stages and faces competition from established players in the healthcare information services market.
What do analysts say about TREIF stock?
As of March 16, 2026, there is no available analyst coverage for Rocket Doctor AI (TREIF). Given the company's small market capitalization of $0.04 billion and its listing on the OTC Other market, it is unlikely to be followed by major research firms. Investors should conduct their own thorough due diligence and consider the risks associated with investing in a micro-cap stock with limited analyst coverage. Key valuation metrics, such as P/E ratio and profit margin, indicate current unprofitability.
What are the main risks for TREIF?
Rocket Doctor AI faces several key risks, including intense competition in the healthcare information services sector, the complex and evolving regulatory landscape, and the potential for technological obsolescence. The company's limited financial resources and negative profit margin also pose significant challenges. As an OTC Other stock, TREIF is subject to less regulatory oversight and greater price volatility. Investors should carefully consider these risks before investing in Rocket Doctor AI.
What are the key factors to evaluate for TREIF?
Evaluating TREIF involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Innovative AI-powered healthcare solutions. Primary risk to monitor: Intense competition in the healthcare information services sector. This is not financial advice.
How frequently does TREIF data refresh on this page?
TREIF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven TREIF's recent stock price performance?
Recent price movement in Rocket Doctor Ai Inc. (TREIF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative AI-powered healthcare solutions. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider TREIF overvalued or undervalued right now?
Determining whether Rocket Doctor Ai Inc. (TREIF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying TREIF?
Before investing in Rocket Doctor Ai Inc. (TREIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Rocket Doctor AI due to its small size and OTC listing.
- AI analysis pending for TREIF.